EUVIMEDEUVIMED entdecken
Crossref

Potent Multi‐Target Inhibition of Cholinesterases and Carbonic Anhydrases by Iridium(III)–Phenanthroline Derivatives: Integrated Structure–Activity Relationship, Molecular Docking and Anticancer Cell Culture Studies

Zeynep Köksal iD, Kevser Kübra Kırboğa iD, Fatma Sağır, Çiğdem Şahin

Drug Development Research · 2026

DOI: 10.1002/ddr.70244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Zeynep Köksal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Istanbul Medeniyet University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Carbonic Anhydrase Inhibitors, Iridium, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, a series of novel iridium(III) complexes incorporating 2‐phenylimidazo[4,5‐f][1,10]phenanthroline ligands with different substituents (methyl ( 1a ), isopropyl ( 2a ), methoxy ( 3a ), phenyl ( 4a )) were evaluated for their in vitro inhibitory activities against anticholinesterase (acetylcholinesterase [AChE], butyrylcholinesterase [BChE]) and carbonic anhydrase [hCA I] and [hCA II]) enzymes. Among the tested compounds, 2a demonstrated exceptional potency with IC 50 values of 66.5 ± 9.06 nM for AChE and 26.45 ± 5.00 nM for BChE, significantly outperforming tacrine. Compound 4a also exhibited strong inhibition of hCA I (IC 50 = 33.0 ± 7.09 nM) and hCA II (IC 50 = 41.79 ± 8.09 nM), surpassing the reference drug acetazolamide. Molecular docking studies revealed that compound 4a exhibited the strongest binding affinity with BChE (PDB: 4BDS) at ‐12.06 kcal/mol, while compound 2a showed strong binding to hCA II (PDB: 3HS4) at ‐8.768 kcal/mol. Molecular dynamics simulations over 150 ns confirmed the structural stability of the protein‐ligand complexes. Cell viability assays showed that compounds 1a–4a decreased PC3 prostate cancer cell viability in a concentration‐dependent manner, with IC 50 values of 10.09, 3.95, 11.39, and 4.51 µM, respectively. This comprehensive study highlights iridium(III) complexes as multitarget therapeutic agents with potent anticholinesterase and carbonic anhydrase inhibitory properties, offering promise for treating neurodegenerative and metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinesterase InhibitorsCarbonic Anhydrase InhibitorsIridiumAntineoplastic AgentsPhenanthrolinesHumansStructure-Activity RelationshipMolecular Docking SimulationAcetylcholinesteraseCell Line, TumorCarbonic Anhydrase IIButyrylcholinesteraseCell Survival

Stichwörter der Autor:innen

acetylcholinesterasesanticancercarbonic anhydrasesinhibitioniridium(III) complexesmolecular dockingmolecular dynamics simulations

Substanzen

Cholinesterase InhibitorsCarbonic Anhydrase InhibitorsIridiumAntineoplastic AgentsPhenanthrolinesAcetylcholinesteraseCarbonic Anhydrase IIButyrylcholinesterase

Autor:innen und Institutionen

  • Department of Chemistry, Istanbul Medeniyet University, Istanbul, Türkiye.
  • Science and Advanced Technologies Research Center (BILTAM), Istanbul Medeniyet University, Istanbul, Türkiye.
  • Department of Bioengineering, Bilecik Seyh Edebali University, Bilecik, Türkiye.
  • Department of Molecular Biology and Genetics, Istanbul Medeniyet University, Istanbul, Türkiye.
  • Department of Engineering Basic Sciences, Istanbul Medeniyet University, Istanbul, Türkiye.

ORCID-Profile: Zeynep Köksal, Kevser Kübra Kırboğa

Zitieren

APA

Köksal, Z., Kırboğa, K. K., Sağır, F., & Şahin, Ç. (2026). Potent Multi‐Target Inhibition of Cholinesterases and Carbonic Anhydrases by Iridium(III)–Phenanthroline Derivatives: Integrated Structure–Activity Relationship, Molecular Docking and Anticancer Cell Culture Studies. Drug Development Research. https://doi.org/10.1002/ddr.70244

Vancouver

Köksal Z, Kırboğa KK, Sağır F, Şahin Ç. Potent Multi‐Target Inhibition of Cholinesterases and Carbonic Anhydrases by Iridium(III)–Phenanthroline Derivatives: Integrated Structure–Activity Relationship, Molecular Docking and Anticancer Cell Culture Studies. Drug Development Research. 2026. doi:10.1002/ddr.70244

BibTeX
@article{Kksal2026,
  author = {Köksal, Zeynep and Kırboğa, Kevser Kübra and Sağır, Fatma and Şahin, Çiğdem},
  title = {Potent Multi‐Target Inhibition of Cholinesterases and Carbonic Anhydrases by Iridium(III)–Phenanthroline Derivatives: Integrated Structure–Activity Relationship, Molecular Docking and Anticancer Cell Culture Studies},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70244}
}
Kostenlos starten →